Evidence review
Is GLP-1 telehealth legal in my state?
The three questions that actually determine whether a GLP-1 telehealth provider can legally treat you — prescriber licensure, pharmacy licensure, and coverage.
In this brief
The Desk's #1 pick
CoreAge Rx
94 · AThe steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Visit CoreAge Rx- Semaglutide
- $149/mo
- Tirzepatide
- $349/mo
- Coverage
- All 50 states
- Access
- Compounded
Advertising disclosure · we may earn a commission at no extra cost to you. It never changes a Brief Score.
Also on the board
Trimi
89 · B+A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.
Visit Trimi'Is this legal in my state?' is a fair question to ask about any GLP-1 telehealth provider, and the honest answer is that it's rarely a single yes-or-no — it depends on three separate legal questions that a provider either clears or doesn't. Here's the actual framework, rather than a state-by-state guess.
Question 1: Is the prescriber licensed in your state?
Medical licensure in the US is state-based: a prescriber generally needs to hold a license in the state where the patient is physically located at the time of the visit, not just where the clinic is headquartered. Legitimate telehealth companies solve this by employing or contracting with clinicians licensed in every state they serve, and by geofencing or otherwise confirming your location before prescribing. A position paper from the American College of Physicians on telemedicine policy underscores how much this licensure patchwork still shapes what's legally possible across state lines, even as telehealth has become mainstream1. If a provider can't clearly confirm a prescriber licensed in your specific state, that's a real red flag, not a technicality.
Question 2: Is the pharmacy licensed to ship into your state?
Separately from the prescriber, the pharmacy filling your prescription — whether it's dispensing a brand-name product or compounding semaglutide or tirzepatide — generally needs its own licensure to ship into your state, often as a 'non-resident pharmacy.' This is true whether the pharmacy is a standard retail pharmacy or a 503A/503B compounding facility. A provider can have a perfectly licensed prescriber and still be unable to legally fill your prescription if its pharmacy partner isn't licensed for your state specifically. This is exactly the kind of detail covered in our compounded-pharmacy vetting checklist in is compounded semaglutide legit? — a named, accredited pharmacy that can actually confirm it serves your state is the concrete thing to look for.
Question 3: Does your insurance or the drug's regulatory status change anything?
Semaglutide and tirzepatide are not federally controlled substances, so the additional layer of telehealth regulation that applies to controlled-substance prescribing (like certain ADHD medications) generally doesn't apply here in the same way. What can still matter is whether your specific insurance plan requires an in-person visit for coverage purposes even where telehealth prescribing itself is legal — a coverage question, not a legality one, covered in our insurance coverage guide. Broader federal telehealth coverage policy, including for Medicare, has continued to evolve, which is part of why 'is telehealth legal' and 'is telehealth covered' can have different answers even for the same visit2.
What this looks like in practice
A legitimate GLP-1 telehealth provider should be able to tell you plainly, before you pay anything: whether it currently serves your state, whether its prescribers are licensed there, and whether its pharmacy partner is licensed to ship there. A study of a remote weight-management program built around semaglutide and tirzepatide reported real-world outcomes over 12 months, which is a useful reminder that well-run telehealth GLP-1 care is a mainstream, functioning model when the licensure pieces are actually in place — not an inherently grey-market arrangement3.
What to actually check before you sign up
Ask directly, in writing if possible: 'Is your prescriber licensed in [your state], and is your pharmacy licensed to ship there?' A provider that answers both questions specifically and confidently has almost certainly done the compliance work; one that's vague or changes the subject to price hasn't necessarily done anything illegal, but it also hasn't shown you it's checked. This sits alongside the rest of our 5-minute provider checklist, and if you're weighing compounded against brand-name options specifically, see compounded vs brand-name GLP-1, explained. This is general regulatory information, not legal advice for your specific situation — your state's medical and pharmacy boards are the authoritative source if you need a definitive answer.
Frequently asked questions
Is it legal for an out-of-state doctor to prescribe me a GLP-1?
Generally, a prescriber needs to be licensed in the state where you're physically located at the time of your visit, not just where the company is based. Legitimate telehealth providers employ or contract with clinicians licensed in every state they serve.
Are semaglutide and tirzepatide controlled substances?
No. They're not federally controlled substances, so the extra layer of telehealth regulation that applies to controlled-substance prescribing generally doesn't apply to GLP-1s in the same way it does to, for example, certain ADHD medications.
If the prescriber is licensed in my state, is that enough?
Not necessarily — the pharmacy filling your prescription, whether dispensing a brand product or compounding it, generally also needs to be licensed to ship into your state. Both pieces need to check out.
How do I actually verify a provider is legitimate for my state?
Ask directly whether its prescribers are licensed in your state and whether its pharmacy partner is licensed to ship there. A provider that answers both clearly has likely done the compliance work; vagueness on either question is worth treating as a caution sign.
References
- Johnson D, Quinn S, Algase LF, Watkins C Jr (2026). Telemedicine Policy and Practice: A Position Paper From the American College of Physicians. Annals of Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/42114091/
- Centers for Medicare & Medicaid Services (2026). Telehealth coverage policy. CMS.gov. https://www.cms.gov/medicare/coverage/telehealth
- Richards R, Lunt W, Whitman M, Spaltro G, Hall R (2025). Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Formative Research. https://pubmed.ncbi.nlm.nih.gov/40838489/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
How to choose a GLP-1 provider: a 5-minute checklist
A plain-English, five-minute checklist for vetting a GLP-1 telehealth provider — price stability, accreditation, supply, and the fine print that matters.
ReadHow much does semaglutide cost, with and without insurance?
What Wegovy, Ozempic, and compounded semaglutide actually cost with insurance, without it, and in the cash-pay telehealth market — and why the numbers vary.
ReadHow much does tirzepatide cost, with and without insurance?
What Zepbound, Mounjaro, and compounded tirzepatide actually cost with insurance, without it, and across the cash-pay telehealth market.
ReadGLP-1 insurance coverage: what's covered, what isn't, and prior authorization
How GLP-1 insurance coverage actually works — the diabetes-vs-obesity split, prior authorization, Medicare's exclusion, and how to check your own plan.
ReadCompounded vs brand-name GLP-1, explained
What separates compounded semaglutide and tirzepatide from brand-name Wegovy and Zepbound — on price, regulation, supply, and what the labels actually cover.
ReadSemaglutide vs tirzepatide: what the trials actually show
A plain-English read of the STEP-1, SURMOUNT-1, and SURPASS-2 trials: how much weight each GLP-1 drove, in which patients, and what the head-to-head compared.
Read